肌缩侧面硬化症患者的头痛类型和特征
Radwa Soliman1, Nagia Fahmy2, Mahmoud S Swelam2
1Neurology and Psychiatry Department, Faculty of Medicine Ain Shams University, Cairo, 11566, Egypt. radwasoliman@med.asu.edu.eg.
The journal of headache and pain
|March 13, 2025
概括
脑筋急变侧面硬化症 (ALS) 患者的头痛很常见,许多人经历了像张力类型和偏头痛这样的初级头痛. 对所有类型的头痛进行评估对于ALS患者的护理至关重要.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
- 头痛 医学 医学 医学
背景情况:
- 肌缩侧面硬化 (ALS) 是一种渐进的运动神经元疾病,导致呼吸衰竭和死亡.
- 头痛是神经系统疾病中经常报告的一种症状,但它们在ALS中的患病率和类型并未得到很好的描述.
研究的目的:
- 调查被诊断患有骨髓缩侧面硬化症 (ALS) 的患者经历的头痛的类型和频率.
主要方法:
- 一项横截面研究招募了100名临床确定的ALS患者.
- 用国际头痛协会 (IHS) 的标准评估患者的头痛类型.
- 评估了头痛的影响,抑郁症,ALS严重程度 (ALSFRS-R) 和认知功能 (ECAS-EG).
主要成果:
- 79%的ALS患者报告头痛;62%的患者出现初级头痛 (46%是紧张型,16%是偏头痛).
- 15%的人经历了次要的头痛,主要是由于呼吸不充分 (12%) 或Riluzole开始 (3%).
- 呈现时的平均年龄为43.9岁,平均ALSFRS-R得分为33.3.
结论:
- 在ALS患者中,对头痛的评估至关重要,包括呼吸道损害和初级头痛等二次原因.
- 主要的头痛,如紧张型和偏头痛,可能会被忽视,在ALS治疗中需要注意.
相关概念视频
Parkinson's Disease: Overview
410
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
410
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
Parkinson's Disease: Treatment
174
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
174
Cross-bridge Cycle
116.5K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
116.5K


